Scalper1 News
Mylan (MYL) rejected a takeover bid from Teva Pharmaceutical (TEVA) on Monday but said it was still was committed to its offer for Perrigo (PRGO). The generic pharmaceutical company said the $40 billion offer undervalued the company and “would require Mylan’s shareholders to accept what we believe are low-quality Teva shares in exchange for their high-quality Mylan shares.” Many analysts believe Teva could and would offer more. But Mylan’s fierce Scalper1 News
Scalper1 News